Inclusion Criteria:  Clinically or pathologically confirmed hepatocellular carcinoma. ECOG 0-1. BCLC C Liver-GTV >700ml; intrahepatic metastasis allowed but only one tumor is to be treated with SBRT and others stable for more than 3 months; distant metastasis allowed but stable for more than 6 months. Expected gastric/duodenum/small intestine Dmax 25-35Gy; colon Dmax 28-38Gy. Prescription dose 40Gy/5-10f. DIBH training prior to SBRT to achieve 36 seconds breath hold. Life expectancy > 3 months. Child-Pugh A5, A6 or B7. Liver function: ALT within 1.5 times of upper limit; ALT within 0.5 times of upper limit and AST within 6 times of upper limit, excluding cardiac infarction; ALT within 0.5-1.5 times of upper limit and AST within 1.5 times of upper limit Normal ECG, without severe cardiac dysfunction Kidney function: CRE, BUN within 1.5 times of upper limit. CBC: Hb≥80g/L，ANC≥1.0×109 /L，PLT≥40×109 /L Without hemorrhagic tendency. Voluntarily participate in this trial and sign consent form.  Exclusion Criteria:  Participants of other clinical trials. History of abdomen radiation therapy or liver transplantation. History of severe cardiovascular, kidney or liver disease. Pregnancy or lactation. Suspected or confirmed of drug or alcohol abuse. History of severe mental or neurological disease, compromising the ability to consent and/or AE diagnosis. Allergic to lipiodol.